FDA Drugs (New Approvals & NDA)Original article
Safety Reporting Requirements for INDs and BA/BE Studies
RegulatoryNeutral
AI Analysis
Summary
FDA issued or updated guidance for industry and investigators on safety reporting requirements for INDs and bioavailability/bioequivalence (BA/BE) studies. The notice contains no product-specific or company-specific information.
Outcome Details
FDA guidance document on safety reporting requirements for INDs and BA/BE studies; no specific product decision or outcome.
Importance:3/10
Sentiment:
0.00
FDAguidancedrug safetyINDBA/BEsafety reportingregulatory
Read the original article
Published by FDA Drugs (New Approvals & NDA) on October 19, 2026 4:26 PM